Vaxart, Inc., a biotechnology company based in South San Francisco, USA, specializes in the development and marketing of oral flu vaccines. These vaccines are designed to stimulate the immune system of the gut, generating both systemic and mucosal immune responses. Vaxart serves its global customer base through its website, www.vaxart.com , and trades on the Nasdaq stock exchange.
As of January 22, 2026, Vaxart’s stock closed at $0.67. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $0.84 on January 11, 2026, and a low of $0.26 on July 8, 2025. This represents a 61.9% decline from its peak, indicating a challenging period for the company’s stock performance.
The company’s market capitalization stands at approximately $160.74 million USD. Despite its innovative approach to vaccine delivery, Vaxart’s financial metrics reflect some challenges. The price-to-earnings (P/E) ratio is currently at -3, indicating negative earnings. This suggests that the company is not currently profitable, which is a critical factor for investors considering the stock’s valuation.
Additionally, the price-to-book (P/B) ratio is 6.29, suggesting that the market values the company at roughly six times its book value. While this may indicate investor confidence in the company’s future potential, the high P/B ratio, coupled with negative earnings, highlights the speculative nature of the investment.
In recent developments, Vaxart reported positive data for its oral bivalent norovirus vaccine in lactating women and infants, as per a release from OTCMarkets dated January 15, 2026. This data could be a pivotal point for the company, potentially influencing future research directions and market interest.
Overall, Vaxart’s current financial and operational status presents a mixed picture. While the company continues to innovate in the biotechnology sector with its oral vaccine technology, its financial metrics indicate ongoing profitability challenges. Investors and stakeholders will likely monitor upcoming developments closely, particularly any further data releases or strategic initiatives that could impact the company’s market position and financial health.
